Terms: = Prostate cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Prognosis
187 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. Copy Number Gain in Androgen Receptors Predicts the Poor prognosis in Japanese Castration-resistant prostate cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract] [Full Text] [Related]
3. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
4. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients.
Samaratunga H; Egevad L; Yaxley J; Perry-Keene J; Le Fevre I; Kench J; Matsika A; Bostwick D; Iczkowski K; Delahunt B
Pathology; 2024 Feb; 56(1):33-38. PubMed ID: 38071161
[TBL] [Abstract] [Full Text] [Related]
5. Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients.
Wang X; Zeng M; Ju X; Lin A; Zhou C; Shen J; Liu Z; Tang B; Cheng Q; Wang Y; Zhang J; Luo P
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38055899
[TBL] [Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
8. Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer.
Zhang Z; Cai Q; Wang J; Yao Z; Ji F; Hang Y; Ma J; Jiang H; Yan B; Zhanghuang C
Sci Rep; 2023 Oct; 13(1):17719. PubMed ID: 37853026
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity.
Chen S; Song W; Zhang R; Jin Y; Lu Y; Lin L; Ye L; Li T; Wei Y
Sci Rep; 2023 Jun; 13(1):10317. PubMed ID: 37365217
[TBL] [Abstract] [Full Text] [Related]
10. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
11. Does the Gleason Score 7 Upgrading Always Predict Worse prognosis?
Zhou J; Yu M; Ding J; Qi J
Clin Genitourin Cancer; 2023 Dec; 21(6):e412-e421. PubMed ID: 37248147
[TBL] [Abstract] [Full Text] [Related]
12. Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer.
Payrard-Starck C; Fourcade A; An Nguyen T; Tissot V; Doucet L; Marolleau J; Lucas C; Fournier G; Valeri A
Prog Urol; 2023 Apr; 33(5):265-271. PubMed ID: 36740508
[TBL] [Abstract] [Full Text] [Related]
13. [Outcome of Low-Dose-Rate Brachytherapy in Patients with prostate cancer and the Characteristics of Patients with Recurrence].
Sakatoku N; Miwa S; Sato R; Koshida K
Hinyokika Kiyo; 2023 Jan; 69(1):1-6. PubMed ID: 36727454
[TBL] [Abstract] [Full Text] [Related]
14. cancer incidence and mortality in Quito: information to monitor cancer control policies.
Cueva P; Tarupi W; Caballero H
Colomb Med (Cali); 2022; 53(1):e2024929. PubMed ID: 36415599
[TBL] [Abstract] [Full Text] [Related]
15. Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study.
Cao G; Li Y; Wang J; Wu X; Zhang Z; Zhanghuang C; Han K
Front Public Health; 2022; 10():1028905. PubMed ID: 36330113
[TBL] [Abstract] [Full Text] [Related]
16. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG; Sperger JM; Schehr JL; McKay RR; Emamekhoo H; Singh A; Schultz ZD; Bade RM; Stahlfeld CN; Gilsdorf CS; Hernandez CI; Wolfe SK; Mayberry RD; Krause HM; Bootsma M; Helzer KT; Rydzewski N; Bakhtiar H; Shi Y; Blitzer G; Kyriakopoulos CE; Kosoff D; Wei XX; Floberg J; Sethakorn N; Sharifi M; Harari PM; Huang W; Beltran H; Choueiri TK; Scher HI; Rathkopf DE; Halabi S; Armstrong AJ; Beebe DJ; Yu M; Sundling KE; Taplin ME; Lang JM
J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36317634
[TBL] [Abstract] [Full Text] [Related]
17. Influence of Active Surveillance on Gleason Score Upgrade and prognosis in Low- and Favorable Intermediate-Risk prostate cancer.
Hu X; Miao J; Huang J; Qian L; Zhang D; Wei H
Curr Oncol; 2022 Oct; 29(10):7964-7978. PubMed ID: 36290907
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced prostate cancer: Differences in Genomic Landscape Based on Race.
Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J; Mack A; Ravindranathan D; Maughan BL; Nussenzveig R; Yandell M; Kohli M; Lilly MB; Sartor AO; Agarwal N; Barata PC
Oncologist; 2022 Oct; 27(10):e815-e818. PubMed ID: 36036607
[TBL] [Abstract] [Full Text] [Related]
19. A Web-Based Prediction Model for cancer-Specific Survival of Elderly Patients Undergoing Surgery With prostate cancer: A Population-Based Study.
Zhang Z; Zhanghuang C; Wang J; Mi T; Liu J; Tian X; Jin L; He D
Front Public Health; 2022; 10():935521. PubMed ID: 35903379
[TBL] [Abstract] [Full Text] [Related]
20. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.
Zhao Y; Hu X; Yu H; Liu X; Sun H; Shao C
Cell Mol Life Sci; 2022 Jul; 79(8):436. PubMed ID: 35864178
[TBL] [Abstract] [Full Text] [Related]
[Next]
